NasdaqCM - Nasdaq Real Time Price ? USD ENDRA Life Sciences Inc. (NDRA) Follow Compare 4.5400 -0.7600 (-14.34%) At close: November 15 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich., November 15, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Business Wire ? 2 days ago NDRA -14.34% Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting? 2024 ANN ARBOR, Mich., November 12, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced the acceptance of a poster titled "Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity" for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego. Business Wire ? 5 days ago NDRA -14.34% ENDRA Life Sciences Further Strengthens TAEUS? Platform Intellectual Property with Issuance of 17th European Patent ANN ARBOR, Mich., November 06, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled "Method and System for Monitoring Tissue Temperature." Business Wire ? 11 days ago NDRA -14.34% ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany ANN ARBOR, Mich., October 22, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe. Business Wire ? 26 days ago NDRA -14.34% ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements ANN ARBOR, Mich., August 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Business Wire ? 2 months ago NDRA -14.34% ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich., August 22, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: Business Wire ? 2 months ago NDRA -14.34% ENDRA Life Sciences Announces Reverse Stock Split ANN ARBOR, Mich., August 16, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to trad Business Wire ? 3 months ago NDRA -14.34% ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024 ANN ARBOR, Mich., August 13, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. Business Wire ? 3 months ago NDRA -14.34% ENDRA Life Sciences Announces Leadership Changes ANN ARBOR, Mich., August 13, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head of Business Wire ? 3 months ago NDRA -14.34% ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14 ANN ARBOR, Mich., August 07, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developm Business Wire ? 3 months ago NDRA -14.34% ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering ANN ARBOR, Mich., June 04, 2024--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA" or the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. Business Wire ? 5 months ago NDRA -14.34% ENDRA Provides Update Following In-person Meeting with FDA ANN ARBOR, Mich., May 20, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing. Business Wire ? 5 months ago NDRA -14.34% ENDRA Life Sciences Inc (NDRA) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... Discover how ENDRA Life Sciences Inc navigates its financial landscape and strategic milestones amidst ongoing challenges. GuruFocus.com ? 6 months ago NDRA -14.34% ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich., May 14, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months ended March 31, 2024 and provided a business update. Business Wire ? 6 months ago NDRA -14.34% ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024 ANN ARBOR, Mich., May 07, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer Business Wire ? 6 months ago NDRA -14.34% ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents ANN ARBOR, Mich., May 02, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology. Business Wire ? 6 months ago NDRA -14.34% ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript March 28, 2024 ENDRA Life Sciences Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.36. NDRA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […] Insider Monkey ? 7 months ago NDRA -14.34% Q4 2023 ENDRA Life Sciences Inc Earnings Call Q4 2023 ENDRA Life Sciences Inc Earnings Call Thomson Reuters StreetEvents ? 7 months ago NDRA -14.34% ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ANN ARBOR, Mich., March 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Business Wire ? 7 months ago NDRA -14.34% ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 ANN ARBOR, Mich., March 21, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate develo Business Wire ? 7 months ago NDRA -14.34% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NDRA S&P 500 YTD -99.88% +23.08% 1-Year -99.72% +30.58% 3-Year -99.99% +25.36%
